

HOYA Corporation

FY26 Q1 Earnings Presentation

July 31, 2026

FY26 Q1 Results



FY26 Q1 Overview



- [Revenue] Both the Life Care and Information Technology businesses delivered solid growth, resulting in double-digit revenue growth at the consolidated level.
- [Profit From Ordinary Operating Activities; hereinafter “Operating Profit”] Profitability expanded in both businesses, driving profit growth that outpaced revenue growth.
- Quarterly revenue and operating profit reached record highs.




Cf. ROIC [NOPAT / Invested Capital (Interest-bearing liabilities + equity attributable to the parent company)]: 23.8%

USD	¥160.72	-11.8%
EUR	¥186.13	-12.7%

Life Care Business


- [Revenue] Revenue grew at a double-digit rate, supported by resilient performance across the portfolio and favorable FX translation effects.
- [Operating Profit] Profitability improved significantly YoY, supported by ongoing cost rationalization and operational improvements.

Revenue (¥bn)



+13% (CC +3%)

Operating Profit / OPM



+24% (CC +15%)

Eyeglass Lenses

Sales Growth
+16%
(CC +4%)

- Asia, particularly Japan and China, drove growth. By channel, sales to large retail chains remained robust.
- Sales of MiYOSMART iQ (2nd gen) expanded further in China, while rollout into other markets continued.
- We remain focused on expanding high-value-added products and accelerating market penetration of new products.



Contact Lenses (eyecity)

Sales Growth
+3%
(CC +3%)

- Revenue remained solid, supported by higher customer traffic and improved customer retention through subscription programs and other initiatives.
- The continued expansion of premium product sales increased average spending per customer.
- We will continue to enhance customer convenience and expand sales of premium products to broaden our customer base.



Endoscopes

Sales Growth
+8%
(CC -4%)

- Revenue in Europe remained broadly stable, while weakness in the Chinese market persisted.
- Structural reforms are progressing as planned, including the company split of the Japanese Endoscope business effective August 1 and manufacturing footprint optimization.
- As part of business portfolio management, we have initiated a review of strategic options, including a potential transfer of the business to a third party.



IOLs

Sales Growth
+17%
(CC +9%)

- While revenue declined in China, growth remained solid in Japan, Europe, and other regions.
- The growing adoption of trifocal IOLs increased the share of ATIOLs in the sales mix, contributing to revenue growth.
- We continue to focus on expanding ATIOL sales globally.



Vivinex™ multiSert™

Artificial Bone and Other

Sales Growth
+15%
(CC +6%)


- Sales of endoscope disinfection washers and metal implants remained solid, resulting in double-digit growth.
- Revenue from chromatography media declined due to ongoing customer inventory adjustments.
- We aim to achieve stable and sustainable growth by expanding into new markets and applications while strengthening our operating foundation.



Information Technology Business


- [Revenue] Strong growth in Optical Solutions, in addition to LSI and HDD substrates, contributed to overall revenue expansion.
- [Operating Profit] Profit margins expanded, supported by higher revenue and a richer mix of high-value-added products.

Revenue (¥bn)



+23% (CC +15%)

Operating Profit / OPM



+28% (CC +19%)

Sales Growth
+21%
(CC +18%)

- Demand for EUV blanks remained solid, supported by AI-related semiconductor investment.
- Revenue growth was driven by increased sales of high-value-added EUV blanks, including phase-shift mask (PSM) products.
- We continue to invest in next-generation blanks, including High-NA products, while supporting customers' performance enhancement.



Sales Growth
+9%
(CC +2%)

- Revenue increased as utilization at the Chongqing facility improved and sales to Chinese customers expanded.
- Demand for development projects remained stable, particularly for smartphones, foldable devices, and IT OLED applications.
- We continue to expect growth opportunities from foldable devices, wearables such as VR, and OLED-equipped AI PCs and gaming PCs.



HDD Substrates

Sales Growth
+29%
(CC +15%)

- Strong nearline HDD demand, supported by active data center investment, drove significant growth in 3.5-inch substrates.
- Adoption of HAMR technology and higher platter counts continued to support increased use of glass substrates.
- We are increasing utilization in Laos while enhancing manufacturing capabilities for HAMR applications and thinner substrates required for higher-capacity drives.



Optical Solutions (Formerly Imaging)

Sales Growth
+22%
(CC +11%)

- To better reflect the business portfolio, which now extends beyond camera-related applications, the business has been renamed Optical Solutions beginning this quarter.
- Strong sales of CUPO polarization glass for optical transceivers were the primary driver of growth.
- We continue to expand CUPO production capacity while promoting growth in wearable-device lenses and AR-related products.




Shareholder Returns

- In April, we announced a policy to reduce net cash on the balance sheet by approximately ¥110 billion in order to further enhance capital efficiency.
- Based on this policy and taking into account cash flow generation and investment requirements, we resolved to conduct a share buyback program of up to ¥200 billion.

Concept of Optimal Net Cash Level

(Reprinted from FY25 Q4 presentation)



Share Buyback Program

Period	Aug. 3, 2026 - Mar. 24, 2027
Maximum Amount	¥200 bn
Maximum Shares	10 mn shares (2.99% of the total number of issued shares excluding treasury stock)

Guidance

The Life Care Business and the Information Technology Business are both expected to benefit from continued robust demand for their key products. In particular, eyeglass lenses, EUV blanks, HDD substrates, and optical solutions are expected to drive growth, supporting double-digit increases in both revenue and operating profit.

Q2

(¥bn)	FY25 Q2	FY26 Q2	YoY
Revenue	234.5	265.3	+13%
Operating Profit	70.2	82.6	+18%
Pretax Profit	71.9	84.0	+17%
Profit for the Quarter	55.0	65.2	+19%

H1

(¥bn)	FY25 H1	FY26 H1	YoY
Revenue	459.0	521.0	+15%
Operating Profit	136.4	165.0	+21%
Pretax Profit	139.3	170.0	+22%
Profit for the Period	106.4	131.0	+23%

Forward-looking Statement

HOYA may make comments and disclose information which include forward-looking statements with respect to HOYA's plans and future performance. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements and are based on management's assumptions and beliefs in light of the information available when such statements were prepared, including exchange and interest rates, international situations, market trends and economic conditions, competition, production capacity, estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory, clinical or research and development capabilities, results or practices, customer patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems, and other such estimates and results. HOYA does not guarantee the accuracy or completeness of such information and HOYA does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Notes

- ✓ Accounting standard: IFRS
- ✓ The fiscal year ending March 2027 is referred to as “FY26” throughout this document.
- ✓ Figures less than 100 million yen are rounded. Accordingly, some discrepancies may occur among totals. Ratios are calculated using actual numbers.
- ✓ Operating profit is calculated as reference information for investors; calculated by deducting finance income/costs, share of profits(loss) of associates, FX gain/loss and other temporary gain/loss from pretax profit.
- ✓ We have omitted detailed breakdown of financial statements. Please refer to the tanshin or the quarterly report for detailed numbers.
<https://www.hoya.com/en/investor/kessan/>

Innovating for a Better Tomorrow

HOYA